http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110872348-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-567 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13 |
| filingDate | 2018-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110872348-B |
| titleOfInvention | Humanized anti-CD 47 monoclonal antibody and application thereof |
| abstract | The invention relates to the technical field of antibody medicines, in particular to a humanized anti-CD 47 monoclonal antibody and application thereof. The humanized anti-CD 47 monoclonal antibody provided by the invention can effectively inhibit tumor growth; the dosage-dependent blocking of the combination of human SIRP alpha and human CD47 can promote the phagocytosis of tumor cells by macrophages, prevent the tumor cells from escaping from a defense system of tumor immunity, and play a role in resisting tumors. The combination of CD47 on the surface of the tumor cell and SIRP alpha on the surface of macrophage is blocked, so that 'do-me-eat' signals of the tumor cell can be blocked, the recognition and the uptake of the macrophage to the tumor cell are promoted, and the tumor cell is promoted to be phagocytized. The combination of CD47 on the surface of tumor cells and SIRP alpha on the surface of macrophages is a universal 'eat me' signal, and CD47 can be used as a very promising target spot in the tumor immune system and plays a powerful and effective role in human tumor treatment. |
| priorityDate | 2018-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 618.